000287650 001__ 287650
000287650 005__ 20241031114747.0
000287650 0247_ $$2doi$$a10.3389/fmed.2024.1337367
000287650 0247_ $$2pmid$$apmid:38327708
000287650 0247_ $$2pmc$$apmc:PMC10847215
000287650 0247_ $$2altmetric$$aaltmetric:159249119
000287650 037__ $$aDKFZ-2024-00293
000287650 041__ $$aEnglish
000287650 082__ $$a610
000287650 1001_ $$aReineke, Marvin$$b0
000287650 245__ $$aDynamics of torque teno virus load in kidney transplant recipients with indication biopsy and therapeutic modifications of immunosuppression.
000287650 260__ $$aLausanne$$bFrontiers Media$$c2024
000287650 3367_ $$2DRIVER$$aarticle
000287650 3367_ $$2DataCite$$aOutput Types/Journal article
000287650 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712310244_9904
000287650 3367_ $$2BibTeX$$aARTICLE
000287650 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287650 3367_ $$00$$2EndNote$$aJournal Article
000287650 520__ $$aFollowing kidney transplantation, lifelong immunosuppressive therapy is essential to prevent graft rejection. On the downside, immunosuppression increases the risk of severe infections, a major cause of death among kidney transplant recipients (KTRs). To improve post-transplant outcomes, adequate immunosuppressive therapy is therefore a challenging but vital aspect of clinical practice. Torque teno virus load (TTVL) was shown to reflect immune competence in KTRs, with low TTVL linked to an elevated risk for rejections and high TTVL associated with infections in the first year post-transplantation. Yet, little is known about the dynamics of TTVL after the first year following transplantation and how TTVL changes with respect to short-term modifications in immunosuppressive therapy. Therefore, we quantified TTVL in 106 KTRs with 108 clinically indicated biopsies, including 65 biopsies performed >12 months post-transplantation, and correlated TTVL to histopathology. In addition, TTVL was quantified at 7, 30, and 90 days post-biopsy to evaluate how TTVL was affected by changes in immunosuppression resulting from interventions based on histopathological reporting. TTVL was highest in patients biopsied between 1 and 12 months post-transplantation (N = 23, median 2.98 × 107 c/mL) compared with those biopsied within 30 days (N = 20, median 7.35 × 103 c/mL) and > 1 year post-transplantation (N = 65, median 1.41 × 104 c/mL; p < 0.001 for both). Patients with BK virus-associated nephropathy (BKVAN) had significantly higher TTVL than patients with rejection (p < 0.01) or other pathologies (p < 0.001). When converted from mycophenolic acid to a mTOR inhibitor following the diagnosis of BKVAN, TTVL decreased significantly between biopsy and 30 and 90 days post-biopsy (p < 0.01 for both). In KTR with high-dose corticosteroid pulse therapy for rejection, TTVL increased significantly between biopsy and 30 and 90 days post-biopsy (p < 0.05 and p < 0.01, respectively). Of note, no significant changes were seen in TTVL within 7 days of changes in immunosuppressive therapy. Additionally, TTVL varied considerably with time since transplantation and among individuals, with a significant influence of age and BMI on TTVL (p < 0.05 for all). In conclusion, our findings indicate that TTVL reflects changes in immunosuppressive therapy, even in the later stages of post-transplantation. To guide immunosuppressive therapy based on TTVL, one should consider inter- and intraindividual variations, as well as potential confounding factors.
000287650 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000287650 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287650 650_7 $$2Other$$aimmune monitoring
000287650 650_7 $$2Other$$aimmunosuppression
000287650 650_7 $$2Other$$akidney transplantation
000287650 650_7 $$2Other$$aprecision medicine
000287650 650_7 $$2Other$$atorque teno virus
000287650 7001_ $$aMorath, Christian$$b1
000287650 7001_ $$aSpeer, Claudius$$b2
000287650 7001_ $$aRudek, Markus$$b3
000287650 7001_ $$aBundschuh, Christian$$b4
000287650 7001_ $$aKlein, Julian A F$$b5
000287650 7001_ $$aMahler, Christoph F$$b6
000287650 7001_ $$aKälble, Florian$$b7
000287650 7001_ $$aNusshag, Christian$$b8
000287650 7001_ $$aBeimler, Jörg$$b9
000287650 7001_ $$aZeier, Martin$$b10
000287650 7001_ $$0P:(DE-He78)1d3968d2f0ff3eae55f6b2ea4c474387$$aBartenschlager, Ralf$$b11$$udkfz
000287650 7001_ $$aSchnitzler, Paul$$b12
000287650 7001_ $$aBenning, Louise$$b13
000287650 773__ $$0PERI:(DE-600)2775999-4$$a10.3389/fmed.2024.1337367$$gVol. 11, p. 1337367$$p1337367$$tFrontiers in medicine$$v11$$x2296-858X$$y2024
000287650 8564_ $$uhttps://inrepo02.dkfz.de/record/287650/files/fmed-11-1337367.pdf
000287650 8564_ $$uhttps://inrepo02.dkfz.de/record/287650/files/fmed-11-1337367.pdf?subformat=pdfa$$xpdfa
000287650 909CO $$ooai:inrepo02.dkfz.de:287650$$pVDB
000287650 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1d3968d2f0ff3eae55f6b2ea4c474387$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000287650 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000287650 9141_ $$y2024
000287650 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT MED-LAUSANNE : 2022$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T10:35:27Z
000287650 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T10:35:27Z
000287650 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T10:35:27Z
000287650 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-11T10:35:27Z
000287650 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000287650 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000287650 9201_ $$0I:(DE-He78)F170-20160331$$kF170$$lVirus-assoziierte Karzinogenese$$x0
000287650 9201_ $$0I:(DE-He78)D430-20160331$$kD430$$lVirus-assoziierte Karzinogenese$$x1
000287650 980__ $$ajournal
000287650 980__ $$aVDB
000287650 980__ $$aI:(DE-He78)F170-20160331
000287650 980__ $$aI:(DE-He78)D430-20160331
000287650 980__ $$aUNRESTRICTED